Physician profile
Ryan E Zane
NPI 1669534293
$96,949.53
in general payments reported to CMS, 2019-2025
10 companies · $5,639 in 2025
The $5,639 reported for 2025 was more than what 91% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $7,526 · 2021: $11K · 2022: $12K · 2023: $20K · 2024: $13K · 2025: $5,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $7,102 · Consulting Fee: $5,200 · Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,847.00 |
| Travel and Lodging | $7,102.27 |
| Consulting Fee | $5,200.00 |
| Food and Beverage | $1,378.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $70,869.44 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $22,427.91 | 2019-2024 | Cabenuva, Dovato, Rukobia |
| Janssen Products, Lp | $2,332.26 | 2019-2021 | |
| Janssen Biotech, INC. | $1,171.48 | 2019-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $56.96 | 2021 | |
| Hologic Sales and Service, LLC | $47.79 | 2022-2023 | Thinprep 2000 Processor |
| Janssen Scientific Affairs, LLC | $18.54 | 2023 | Symtuza |
| Alkermes, INC. | $13.59 | 2019 | |
| Theratechnologies INC. | $11.56 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Zane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.